MARKET

ISEE

ISEE

IVERIC bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.440
-0.060
-1.71%
After Hours: 3.440 0 0.00% 16:00 03/31 EDT
OPEN
3.490
PREV CLOSE
3.500
HIGH
3.530
LOW
3.320
VOLUME
206.98K
TURNOVER
--
52 WEEK HIGH
8.97
52 WEEK LOW
0.9059
MARKET CAP
170.93M
P/E (TTM)
-2.4736
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ISEE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ISEE stock price target is 14.00 with a high estimate of 15.00 and a low estimate of 13.00.

EPS

ISEE News

More
  • IVERIC bio Appoints Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer
  • Business Wire · 03/23 21:01
  • New business chief at Iveric bio
  • Seeking Alpha - Article · 03/23 20:16
  • FDA urges virtual patient visits as coronavirus disrupts clinical trials
  • Reuters · 03/18 16:39
  • Iveric bio delays start of second Zimura study due to Covid-19
  • Seeking Alpha - Article · 03/18 14:39

Industry

Biotechnology & Medical Research
-0.26%
Pharmaceuticals & Medical Research
-0.17%

Hot Stocks

Symbol
Price
%Change

About ISEE

IVERIC bio, Inc., formerly Ophthotech Corporation, is a biopharmaceutical company. The Company is focused on the discovering and developing of novel gene therapy solutions to treat orphan inherited retinal diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. The Company’s BEST1 gene encodes a multifunctional protein known as bestrophin1, that regulates ion transport and intracellular calcium signaling in retina cells and helps maintain homeostasis in the sub retinal space between photoreceptors and the retinal pigment epithelial (RPE) cells. Its IC-200 is a mutation independent gene therapy, delivered by an AAV2 vector.
More

Webull offers kinds of IVERIC bio Inc stock information, including NASDAQ:ISEE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISEE stock news, and many more online research tools to help you make informed decisions.